Russell Investments Group Ltd. cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 58.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,090 shares of the company’s stock after selling 27,864 shares during the quarter. Russell Investments Group Ltd.’s holdings in IDEXX Laboratories were worth $5,506,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Chicago Capital LLC boosted its position in IDEXX Laboratories by 1.1% during the second quarter. Chicago Capital LLC now owns 113,341 shares of the company’s stock worth $31,206,000 after acquiring an additional 1,240 shares during the last quarter. HCR Wealth Advisors acquired a new position in IDEXX Laboratories in the 2nd quarter valued at about $218,000. WINTON GROUP Ltd boosted its holdings in IDEXX Laboratories by 20.5% in the 2nd quarter. WINTON GROUP Ltd now owns 5,010 shares of the company’s stock valued at $1,379,000 after purchasing an additional 852 shares during the last quarter. Piedmont Investment Advisors Inc. boosted its holdings in IDEXX Laboratories by 1.9% in the 1st quarter. Piedmont Investment Advisors Inc. now owns 7,633 shares of the company’s stock valued at $1,707,000 after purchasing an additional 144 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in IDEXX Laboratories by 2.2% in the 1st quarter. Swiss National Bank now owns 287,800 shares of the company’s stock valued at $64,352,000 after purchasing an additional 6,100 shares during the last quarter. Hedge funds and other institutional investors own 87.04% of the company’s stock.

In related news, Chairman Jonathan W. Ayers sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $272.75, for a total transaction of $2,727,500.00. Following the sale, the chairman now directly owns 1,035,942 shares of the company’s stock, valued at approximately $282,553,180.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Jonathan W. Ayers sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.26, for a total transaction of $5,245,200.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 73,305 shares of company stock worth $19,402,442. 2.70% of the stock is owned by insiders.

IDXX has been the topic of several recent analyst reports. Credit Suisse Group boosted their target price on shares of IDEXX Laboratories from $282.00 to $293.00 and gave the company an “outperform” rating in a report on Friday, August 16th. Guggenheim began coverage on shares of IDEXX Laboratories in a report on Thursday, May 23rd. They issued a “buy” rating and a $276.00 target price on the stock. Stifel Nicolaus boosted their price target on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the company a “buy” rating in a research note on Monday, July 22nd. Canaccord Genuity reissued a “buy” rating and issued a $285.00 price target on shares of IDEXX Laboratories in a research note on Friday, August 2nd. Finally, Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a research note on Monday. They issued a “neutral” rating and a $277.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. IDEXX Laboratories has a consensus rating of “Buy” and an average target price of $285.29.

Shares of IDEXX Laboratories stock traded down $1.42 on Friday, reaching $269.63. The company had a trading volume of 5,581 shares, compared to its average volume of 365,627. The firm’s 50 day moving average price is $279.08 and its two-hundred day moving average price is $252.99. The firm has a market cap of $23.04 billion, a PE ratio of 63.39 and a beta of 0.85. IDEXX Laboratories, Inc. has a 52-week low of $176.11 and a 52-week high of $292.17. The company has a debt-to-equity ratio of 4.49, a quick ratio of 0.83 and a current ratio of 1.15.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, August 1st. The company reported $1.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.06. The business had revenue of $620.10 million for the quarter, compared to the consensus estimate of $627.10 million. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 765.45%. The business’s revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.23 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 4.86 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Recommended Story: What is dividend yield?

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.